Biography
My name is Elias Shiferaw Mekonen. I completed my BSc in Medical Laboratory Science in 2015 and my MSc in Clinical Hematology and Immunohematology in 2018, both from the University of Gondar in Ethiopia. Since 2015, I have been an academic professional at the University of Gondar, focusing on scientific research, data analysis, and innovative teaching methodologies. Collaborating with colleagues, I have contributed to 22 publications in peer-reviewed journals. In May 2024, I comme...
Biography
My name is Elias Shiferaw Mekonen. I completed my BSc in Medical Laboratory Science in 2015 and my MSc in Clinical Hematology and Immunohematology in 2018, both from the University of Gondar in Ethiopia. Since 2015, I have been an academic professional at the University of Gondar, focusing on scientific research, data analysis, and innovative teaching methodologies. Collaborating with colleagues, I have contributed to 22 publications in peer-reviewed journals. In May 2024, I commenced my PhD studies at the University of New South Wales in Australia. Beyond my professional pursuits, I enjoy playing football, which helps me maintain a healthy and balanced lifestyle.
Research Title: Improving the safety profiles of new antimicrobials
Supervisor: Professor Mark Willcox
Co Supervisor: Professor Naresh Kumar
Research Abstract
Infections caused by multidrug-resistant (MDR) gram-negative bacteria have risen significantly over the past decade, driven by the overuse and misuse of antibiotics. Antimicrobial resistance (AMR) was linked to 1.3 million deaths globally in 2019, with projections reaching 10 million annually by 2050 if unaddressed. The decline in new antibiotic development has led to the increased reliance on polymyxins as last-resort treatments, despite their significant safety concerns, including nephrotoxicity and neurotoxicity.
Antimicrobial peptides (AMPs) are emerging as promising antibiotics with clinical potential. Newer AMPs like Mel4 and RK758 are under investigation for their ability to combat resistant pathogens. To be viable therapeutic options, AMPs must exhibit potent antibacterial activity while minimizing hemolytic and cytotoxic effects. This study aims to evaluate the safety profiles of new AMPs to address these challenges. In alignment with the WHO’s global action plan on AMR, which emphasizes improving surveillance and research, this study seeks to generate critical evidence to enhance the safety of new antimicrobial agents. These findings may contribute to developing safer and more effective alternatives for combating multidrug-resistant infections.
